C4 Therapeutics, Inc.
Spirocyclic degronimers for target protein degradation
Last updated:
Abstract:
This invention provides compounds that have spirocyclic E3 Ubiquitin Ligase targeting moieties (Degrons), which can be used as is or linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.
Status:
Grant
Type:
Utility
Filling date:
22 May 2020
Issue date:
30 Nov 2021